Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)

Registration No. 333-288816

Prospectus Supplement No. 1

(To Prospectus dated July 21, 2025, as supplemented by

Prospectus Supplement No. 1, dated August 22, 2025)

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

12,500,000 Shares of Common Stock</div>

This prospectus supplement no. 1 (this “Prospectus
Supplement”) amends and supplements the prospectus dated July 21, 2025 (as may be supplemented or amended from time to time, the
“Prospectus”) which forms part of our Registration Statement on Form S-1 (Registration Statement No. 333-288816). This Prospectus
Supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information
contained in the attached Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “Securities and
Exchange Commission”) on August 22, 2025 (the “Form 10-Q”). Accordingly, we have attached the Form 10-Q to this Prospectus
Supplement.

This Prospectus Supplement updates and supplements
the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus,
including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if
there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus
Supplement.

Our common stock and public warrants are listed
on Nasdaq Capital Market (“Nasdaq”) under the symbols “CERO” and “CEROW,” respectively. On August
21, 2025, the last quoted sale price of our common stock as reported on Nasdaq was $8.30 per share and the last quoted sale price of our
public warrants as reported on Nasdaq was $0.0149 per warrant.

We are an “emerging growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 8 of the Prospectus.

Neither the Securities and